Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice

There is no consensus on the optimal treatment duration of anti‐PD‐1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti‐PD‐1 discontinuation, the association of treatment duration with progression and anti‐PD‐1 re‐treatment in relapsing patients. Analyses were...

Descripción completa

Detalles Bibliográficos
Autores principales: van Zeijl, Michiel C. T., van den Eertwegh, Alfons J. M., Wouters, Michel W. J. M., de Wreede, Liesbeth C., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan‐Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van der Hoeven, Jacobus J. M., Haanen, John B. A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293478/
https://www.ncbi.nlm.nih.gov/pubmed/34520567
http://dx.doi.org/10.1002/ijc.33800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293478/
https://www.ncbi.nlm.nih.gov/pubmed/34520567
http://dx.doi.org/10.1002/ijc.33800

Ejemplares similares